10,11-methylenedioxy-20-camptothecin has been researched along with Colonic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertrand, R; Goldman, J; Kerrigan, D; Kohn, KW; Nieves-Neira, W; O'Connor, PM; Pommier, Y | 1 |
| Bertrand, R; Kerrigan, D; Kohn, KW; O'Connor, PM; Pommier, Y | 1 |
2 other study(ies) available for 10,11-methylenedioxy-20-camptothecin and Colonic Neoplasms
| Article | Year |
|---|---|
S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.
Topics: Animals; Aphidicolin; Camptothecin; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA Polymerase II; DNA Replication; DNA, Neoplasm; Humans; Molecular Structure; S Phase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1991 |
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.
Topics: Camptothecin; Colonic Neoplasms; Colony-Forming Units Assay; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Topoisomerase I Inhibitors | 1990 |